Rich Ericson C. King
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rich Ericson C. King has a total of 33 co-authors. Here are the top co-authors by number of shared publications:
- Andrea R. Villaruel
University of the Philippines-Philippine General Hospital
1 shared publication - Anisah Hayaminnah D. Alonto
Department of Neurosciences, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines
1 shared publication - Carl Froilan D. Leochico
Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada
1 shared publication Cary Amiel G. Villanueva
Division of Pulmonary Medicine, Department of Medicine, Philippine General Hospital, University of the Philippines Manila, Manila, Philippines
1 shared publicationCyril Jonas M. Planilla
Division of Medical Oncology, Department of Medicine, College of Medicine and Philippine General Hospital, University of the Philippines Manila, Manila, Philippines
1 shared publication- Dennis Lee Sacdalan
Disease Molecular Biology and Epigenetics Laboratory, National Institute of Molecular Biology and Biotechnology, University of the Philippines Diliman, Quezon City 1101, Philippines
1 shared publication
Latest Publications
- 15 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3138-3139
Beyond the breakthrough for RAS-driven cancers
- 15 September 2026
- Published by Springer Nature in Nature Medicine
- Vol. 32 (9) , 3138-3139
Beyond the breakthrough for RAS-driven cancers
- Open Access
- 30 May 2026
- Published by University of the Philippines Manila in Acta Medica Philippina
- Vol. 60 (10) , 175-195
Philippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Musculoskeletal Disorders
Background and Objective. Musculoskeletal diseases (MSDs) are acutely or chronically painful conditions that cause limitations in mobility, dexterity, and participation in society. They are a major contributor to years lived with disability worldwide and their burden is higher in countries with a lower sociodemographic index, like the Philippines. The goal of this clinical practice guideline (CPG) is to provide recommendations to primary care providers on screening for MSDs among asymptomatic, apparently healthy children and adults. Methods. Following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to CPG development recommended in the Department of Health Manual, the evidence of net benefit or harm of screening for nine musculoskeletal conditions and risk factors was obtained through systematic literature search. Information on cost-effectiveness, patient values and preferences, acceptability, feasibility of screening, and its impact on equity were also obtained. The final recommendations were formulated through consensus by a panel of representatives from multiple stakeholder groups. Results. There were 15 recommendations formulated. Strong recommendations were given to screen for physical inactivity among adults, fall risks and sarcopenia for adults aged ≥60 years old, and osteoporosis among women aged ≥65 years old. However, strong recommendations were made against screening for low vitamin D among infants, children, and adults, and against screening for osteoporosis among men and among women aged <65 years old. Conclusion. Through a comprehensive evaluation of the best available evidence using the GRADE approach, the Task Force developed 15 recommendations on screening and risk factor assessment for nine MSDs. These recommendations will serve as guidance on screening for MSDs at the primary care level.
- 30 May 2026
- Published by University of the Philippines Manila in Acta Medica Philippina
- Vol. 60 (10) , 175-195
Open AccessPhilippine Clinical Practice Guidelines for Periodic Health Examination: Screening for Musculoskeletal Disorders
Background and Objective. Musculoskeletal diseases (MSDs) are acutely or chronically painful conditions that cause limitations in mobility, dexterity, and participation in society. They are a major contributor to years lived with disability worldwide and their burden is higher in countries with a lower sociodemographic index, like the Philippines. The goal of this clinical practice guideline (CPG) is to provide recommendations to primary care providers on screening for MSDs among asymptomatic, apparently healthy children and adults. Methods. Following the Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach to CPG development recommended in the Department of Health Manual, the evidence of net benefit or harm of screening for nine musculoskeletal conditions and risk factors was obtained through systematic literature search. Information on cost-effectiveness, patient values and preferences, acceptability, feasibility of screening, and its impact on equity were also obtained. The final recommendations were formulated through consensus by a panel of representatives from multiple stakeholder groups. Results. There were 15 recommendations formulated. Strong recommendations were given to screen for physical inactivity among adults, fall risks and sarcopenia for adults aged ≥60 years old, and osteoporosis among women aged ≥65 years old. However, strong recommendations were made against screening for low vitamin D among infants, children, and adults, and against screening for osteoporosis among men and among women aged <65 years old. Conclusion. Through a comprehensive evaluation of the best available evidence using the GRADE approach, the Task Force developed 15 recommendations on screening and risk factor assessment for nine MSDs. These recommendations will serve as guidance on screening for MSDs at the primary care level.
- Open Access
- 27 June 2022
- Published by Scientific Scholar in Asian Journal of Oncology
Antioxidants in the Prevention of Cisplatin-Induced Hearing Loss: A Systematic Review and Meta-Analysis
Background Cisplatin is a commonly used chemotherapeutic drug that is associated with irreversible hearing loss. A number of antioxidants have been investigated for prevention, but data have so far been inconclusive. Objective The objective of this study was to assess the efficacy of various antioxidant therapies in preventing hearing loss among adult patients treated with cisplatin. Methodology We searched for controlled clinical trials evaluating various antioxidants as prevention against cisplatin-induced hearing loss in adults. The primary outcome is the proportion of patients with hearing loss. Secondary outcomes include audiometric threshold shifts, tinnitus, tumor response, adverse events, and quality of life. Results Thirteen randomized trials comprising of nine antioxidant therapies were included. Only coenzyme Q with multivitamins demonstrated significant benefit in preventing cisplatin-induced hearing loss (relative risk: 0.15, 95% confidence interval: 0.04–0.58) in a small study, while data for the rest of the agents were inconclusive. Audiometric threshold shifts were significantly lower in the intervention arm for aspirin, vitamin E, and transtympanic dexamethasone. The available data on tumor response was inconclusive, with no definite evidence of diminished tumor response noted. Adverse events noted include mild ear pain particularly for transtympanic therapies. There was no data available on quality of life. Conclusion The current available evidence is so far insufficient to establish any benefit for antioxidant therapies for the prevention of cisplatin-induced hearing loss. More high-quality studies are needed to fill in the identified gaps in knowledge.
- 27 June 2022
- Published by Scientific Scholar in Asian Journal of Oncology
Open AccessAntioxidants in the Prevention of Cisplatin-Induced Hearing Loss: A Systematic Review and Meta-Analysis
Background Cisplatin is a commonly used chemotherapeutic drug that is associated with irreversible hearing loss. A number of antioxidants have been investigated for prevention, but data have so far been inconclusive. Objective The objective of this study was to assess the efficacy of various antioxidant therapies in preventing hearing loss among adult patients treated with cisplatin. Methodology We searched for controlled clinical trials evaluating various antioxidants as prevention against cisplatin-induced hearing loss in adults. The primary outcome is the proportion of patients with hearing loss. Secondary outcomes include audiometric threshold shifts, tinnitus, tumor response, adverse events, and quality of life. Results Thirteen randomized trials comprising of nine antioxidant therapies were included. Only coenzyme Q with multivitamins demonstrated significant benefit in preventing cisplatin-induced hearing loss (relative risk: 0.15, 95% confidence interval: 0.04–0.58) in a small study, while data for the rest of the agents were inconclusive. Audiometric threshold shifts were significantly lower in the intervention arm for aspirin, vitamin E, and transtympanic dexamethasone. The available data on tumor response was inconclusive, with no definite evidence of diminished tumor response noted. Adverse events noted include mild ear pain particularly for transtympanic therapies. There was no data available on quality of life. Conclusion The current available evidence is so far insufficient to establish any benefit for antioxidant therapies for the prevention of cisplatin-induced hearing loss. More high-quality studies are needed to fill in the identified gaps in knowledge.
- 1 December 2021
- Published by Elsevier in Current Problems in Cancer
- Vol. 45 (6) , 100713
Rare case of intramedullary spinal cord metastasis from nasopharyngeal carcinoma
- 1 December 2021
- Published by Elsevier in Current Problems in Cancer
- Vol. 45 (6) , 100713
Rare case of intramedullary spinal cord metastasis from nasopharyngeal carcinoma
- Open Access
- 1 January 2020
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 11 (10) , 309-316
Follicular Dendritic Cell Sarcoma of the Tonsil: A Multimodality Approach
Follicular dendritic cell sarcoma (FDCS) accounts for < 0.4% of soft tissue sarcomas. Only 35 cases of tonsillar FDCS have been reported, and majority had localized presentation. We present a case of FDCS of the tonsil, wherein a well-coordinated trimodality approach provided good disease control in advanced disease. A 53-year-old man presented with a painless and enlarging neck mass of 11-month duration, with no other symptoms. Close examination revealed a 10 × 5 cm mass at the left carotid triangle, and a 3.2 × 2.2 cm mass at the left tonsillar fossa. Imaging revealed the tumor to be unresectable due to its attachment to the great vessels. There were no distant metastases. Biopsy and immunohistochemistry were initially deemed consistent with an undifferentiated sarcoma. Palliative chemotherapy was given using single agent doxorubicin and subsequent dacarbazine, resulting in partial response and stable disease, respectively. Pathological re-evaluation was pursued because of the uncharacteristic slow progression of the tumor, revealing diffuse positivity for CD21 and negative for CD1A and CD34, consistent with FDCS. The patient underwent three cycles of gemcitabine plus docetaxel resulting in 50% regression. This allowed dissection of level IB-V lymph nodes and subsequent radiotherapy for the neck and tonsillar mass, with weekly gemcitabine as a radiosensitizer. Evaluation 8 months post-treatment showed no signs of disease progression. Treatment-related complications included radiation dermatitis and swallowing dysfunction, which both resolved on follow-up. This case highlights the multidisciplinary management of a rare type of sarcoma in an uncommon anatomic location. Precise pathologic diagnosis is important in soft tissue sarcoma because of its therapeutic implications. For FDCS, effective response may still be achieved in the third-line setting. J Med Cases. 2020;11(10):309-316 doi: https://doi.org/10.14740/jmc3551
- 1 January 2020
- Published by Elmer Press, Inc. in Journal of Medical Cases
- Vol. 11 (10) , 309-316
Open AccessFollicular Dendritic Cell Sarcoma of the Tonsil: A Multimodality Approach
Follicular dendritic cell sarcoma (FDCS) accounts for < 0.4% of soft tissue sarcomas. Only 35 cases of tonsillar FDCS have been reported, and majority had localized presentation. We present a case of FDCS of the tonsil, wherein a well-coordinated trimodality approach provided good disease control in advanced disease. A 53-year-old man presented with a painless and enlarging neck mass of 11-month duration, with no other symptoms. Close examination revealed a 10 × 5 cm mass at the left carotid triangle, and a 3.2 × 2.2 cm mass at the left tonsillar fossa. Imaging revealed the tumor to be unresectable due to its attachment to the great vessels. There were no distant metastases. Biopsy and immunohistochemistry were initially deemed consistent with an undifferentiated sarcoma. Palliative chemotherapy was given using single agent doxorubicin and subsequent dacarbazine, resulting in partial response and stable disease, respectively. Pathological re-evaluation was pursued because of the uncharacteristic slow progression of the tumor, revealing diffuse positivity for CD21 and negative for CD1A and CD34, consistent with FDCS. The patient underwent three cycles of gemcitabine plus docetaxel resulting in 50% regression. This allowed dissection of level IB-V lymph nodes and subsequent radiotherapy for the neck and tonsillar mass, with weekly gemcitabine as a radiosensitizer. Evaluation 8 months post-treatment showed no signs of disease progression. Treatment-related complications included radiation dermatitis and swallowing dysfunction, which both resolved on follow-up. This case highlights the multidisciplinary management of a rare type of sarcoma in an uncommon anatomic location. Precise pathologic diagnosis is important in soft tissue sarcoma because of its therapeutic implications. For FDCS, effective response may still be achieved in the third-line setting. J Med Cases. 2020;11(10):309-316 doi: https://doi.org/10.14740/jmc3551
- Open Access
- 25 November 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_9) , ix136-ix137
Herbal product and dietary supplement intake among patients at the Philippine General Hospital (PGH) medical oncology clinic: A cross-sectional survey
Background: The use of herbal products and dietary supplements (HDS) seem to be common among Filipinos. Among patients living with cancer, this is an important concern due to potential adverse effects and harmful interactions with conventional systemic therapy. Unfortunately, data is lacking regarding the prevalence and patterns of HDS use in this population.
- 25 November 2018
- Published by Elsevier in Annals of Oncology
- Vol. 29 (suppl_9) , ix136-ix137
Open AccessHerbal product and dietary supplement intake among patients at the Philippine General Hospital (PGH) medical oncology clinic: A cross-sectional survey
Background: The use of herbal products and dietary supplements (HDS) seem to be common among Filipinos. Among patients living with cancer, this is an important concern due to potential adverse effects and harmful interactions with conventional systemic therapy. Unfortunately, data is lacking regarding the prevalence and patterns of HDS use in this population.